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Introduction
This update of the guidelines for neonatal parenteral 
nutrition (PN) prescription is divided into two parts:
- Part I, which is included in the same issue of the journal, 
wherein the general aspects and criteria for fluids, 
energy, and macronutrients prescriptions, particularly 
for very and extremely preterm infants, are reviewed.  
- Part II, which is included herein, wherein the criteria 
for micronutrients prescription, recommendations for 
either using individualized prescription with hospital 
pharmacy compounding or commercial ready-to-use 
solutions, and PN recommendations in particular clinical 
conditions are reviewed. 
Levels of evidence (LoE) and recommendation grades 
(RG) used in the updated guidelines of the European 
Society of Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) and the European Society for 
Clinical Nutrition and Metabolism (ESPEN), supported 
by the European Society of Paediatric Research (ESPR) 
together with the Chinese Society of Parenteral and 
Enteral Nutrition (CSPEN)1 are adopted in this document 
and shown in the Appendix 1.
Appendix 2 provides a table for the rapid consulting of a 
complete PN prescription in preterm infants.
Keywords: Infant, Newborn; Infant Nutritional 
Physiological Phenomena; Infant, Premature; 
Micronutrients; Parenteral Nutrition Solutions; 
Parenteral Nutrition; Practice Guidelines as Topic
1. Individualized prescription
1.1. Sodium (Table 1)
Comments:
- Sodium (Na): 1 mmol = 1 mEq = 23 mg3.
- In preterm infants, a physiological negative sodium 
balance should be allowed in the first postnatal days; 
otherwise, it may predispose to morbidity, including 
patent ductus arteriosus and bronchopulmonary 
dysplasia.4,5 Some authors have reported that the 
administration of sodium from the first postnatal day 
is not associated with hypernatremia.6-8 Nevertheless, 
most scientific societies2,7,9 recommend that sodium 
should not be administered in the first postnatal day 
or not exceed 2 mEq/kg/day until 6% of birth weight 
is lost.2,5 This interpretation will be biased if the weight 
loss results from the transepidermal loss of water 
(not from natriuresis) due to insufficient environment 
humidity provision5,10-12 (Part I, sections 10.1 and 11.1).
- During the first postnatal week, serum sodium 
predominantly reflects the hydration status and 
subsequently it also indicates the sodium reserve.3,5 
Hypernatremia in the first postnatal days may result 
from dehydration secondary to excessive transepidermal 
water loss or inadequate sodium intake.2 Hyponatremia 
may result from hemodilution secondary to oliguria, 
diuretics, and caffeine use, or sodium renal loss in very 
and extremely preterm infants.2,7 
- When calculating the sodium intake, the amount 
carried by drug salts and saline infusion should be taken 
into account.7,12
- If the sodium requirements are much higher than 
Luís Pereira-da-Silva1,2,3, Susana Pissarra1,4, Ana Margarida Alexandrino5, Luísa Malheiro6, Israel Macedo3,7,
 Manuela Cardoso8, Pedro Vieira da Silva7,9, Simão Pedro Frutuoso5, Helga Lau10, Teresa Soares11, on behalf  of  the 
Portuguese Neonatal Society
Port J Pediatr 2019;50:220-31
DOI: https://doi.org/10.25754/pjp.2019.16027
Guidelines for Neonatal Parenteral Nutrition: 
2019 Update by the Portuguese Neonatal Society. Part II. 
Micronutrients, Ready-to-use Solutions and Particular Conditions
1. Committee on Nutrition of the Portuguese Neonatal Society
2. Neonatal Intensive Care Unit, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
3. Faculdade de Ciências Médicas | NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal
4. Neonatal Intensive Care Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
5. Neonatal Intensive Care Unit, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
6. Neonatal Intensive Care Unit, Hospital da Senhora da Oliveira, Guimarães, Portugal
7. Neonatal Intensive Care Unit, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
8. Nutrition Unit, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
9. Unidade de Neonatologia, Hospital Lusíadas, Lisbon, Portugal
10. Pharmaceutical Services, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal




NICU, Hospital Dona Estefânia, Rua Jacinta Marto,
1169-045 Lisboa, Portugal
Received: 12/12/2018 | Accepted: 02/04/2019
GUIDELINES
221Portuguese Journal of  Pediatrics
recommended, the baseline intake should be provided 
by PN and the supplemental amount infused by an 
independent line through a Y-connection system with 
PN infusion using, for example, sodium chloride (NaCl) 
Guidelines for Neonatal Parenteral Nutrition
APPENDIX 1 - Levels of evidence and recommendation grades1
Levels of Evidence (LoE)
LoE Type of evidence
1++ High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
Recommendation grades (RG) according to the level of evidence
RG Level of evidence
A
At least one meta-analyses, systematic reviews or RCT rated as 1++, and directly applicable to the target population; or 
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating the overall 
consistency of the results
B
A body of evidence including studies rated as 2++, directly applicable to the target population; or
A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of 
results; or Extrapolated evidence from studies rated as 1++ or 1+
0 Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2++ or 2+
GPP Good practice points: Recommended best practice based on the clinical experience of the guideline development group
RCT - randomized control trial.
APPENDIX 2 - Rapid consulting – Daily doses for preterm infants
First postnatal day Daily increase Maximum
 Fluids (mL/kg/d) 60-100humidity 80%-90% 10-15 160-180
 Energy (kcal/kg/day) 45-55 - 90-120
 Glucose (mg/kg/min) 4-8 qs for glycemia45-120 mg/dL
12
 Amino acids (g/kg/day) > 1.5 0.5-1 3.5
 Lipids (g/kg/day) 1-2 0.5-1 4
 Sodium (mEq/kg/day)
0-2 
Initiate preferably after > 6% 
birthweight lost
-  3-5(up to 7)
 Chloride (mEq/kg/day) Similar to sodium -  Similar to sodium
 Potassium (mEq/kg/day) 1-3Initiate after urine output > 1 mL/kg/h - 1-3
 Calcium (mg/kg/day) 32-80 - 100-140(alternative 88-90)
 Phosphorus (mg/kg/day) Divide calcium dose by 1.3 Divide calcium dose by 1.3 Divide calcium dose by 1.3
 Magnesium (mEq/kg/day) 0.2-0.4 - 0.4-0.6
 Water soluble vitamins (mL/kg/day)
 (Soluvit N Infant®)
1 - 1
 Lipid soluble vitamins (mL/kg/day)
 (Vitalipid N Infant®)
1-2 1 4
 Trace elements
   < 2 weeks of exclusive PN Zinc 400-500 µg/kg/day - Zinc 400-500 µg/kg/day
   > 2 weeks of exclusive PN - - Peditrace
® 1 mL/kg/day
+ Zinc (to make up 400-500 µg/kg/day)
PN - parenteral nutrition; qs - quantum satis.
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20% (1 mL = 3.4 mEq); this method is convenient for 
adjusting the dose according to the serum sodium 
levels. 
Parameters guiding the prescription:
- Serum sodium levels: Reference values 135-145 mEq/L.3
- Urinary sodium: A urine spot with Na < 20 mEq/L 
associated with hyponatremia, or a fractional excretion 
of sodium (FENa) < 3% in term infants or < 4% in preterm 
infants, may indicate volume depletion, whereas FENa > 
3% in term infants and > 4% in preterm infants with renal 
insufficiency is more consistent with acute kidney injury.13
1.2. Chloride (Table 2)
Comments:
- Chloride (Cl): 1 mmol = 1 mEq = 35.5 mg.3
- The chloride intake usually parallels the sodium intake 
and the chloride dose should not exceed that of sodium 
and potassium to avoid hyperchloremic metabolic 
acidosis.7
- In preterm infants, excessive chloride intake is associated 
with hyperchloremic metabolic acidosis (Cl > 114 mEq/L).2,9 
This can be prevented or resolved by partially replacing 
chloride with acetate; for example, by administering the 
first 3 mmol/L of anion as chloride and the following 6 
mmol/L as acetate; if more anion is necessary, chloride 
should be added again.9 An alternative is administering 
70% anion as chloride and 30% as acetate, although at 
the beginning very and extremely preterm infants may 
require all of the anion as acetate.3
- Prolonged use of loop diuretics may lead to 
hypochloremia.14
- Chloride excretion may occur in equilibrium with the 
bicarbonate levels; metabolic alkalosis may indicate 
chloride deficiency and acidosis may be associated with 
hyperchloremia.9
Parameters guiding the prescription:
- Serum chloride levels: Reference values 96-106 mEq/L.3
- Blood gases: For the surveillance of alkalosis and acidosis.9
1.3. Potassium (Table 3)
Comments:
- Potassium (K): 1 mmol = 1 mEq = 39 mg.3
- Although some authors have reported that the routine 
administration of potassium from the first postnatal day 
is not associated with hyperkalemia,6 most scientific 
societies recommend that it should be started after 
the establishment of a diuresis ≥ 1 mL/kg/h and in the 
absence of hyperkalemia.2,7,9 If these criteria are met 
in the first postnatal day, potassium can be started 
cautiously, especially in preterm infants.2
- In preterm infants, hyperkalemia may occur with or 
without oliguria; non-oliguric hyperkalemia can result 
from the absorption of hematoma, hemolysis, lack 
of administration of prenatal corticosteroids,2 and in 
extremely preterm infants it results mostly from a 
postnatal intracellular to extracellular potassium shift.15 
In preterm infants, hypokalemia can result from an 
inadequate supply in the face of enhanced demands, 
renal losses, and diuretics or caffeine use.2,14
- In ventilated infants, sudden changes in serum 
potassium may be a consequence of changes in acid-
base balance. Hyperkalemia results from metabolic 
acidosis with acidemia due to a net shift of potassium 
from the intracellular to the extracellular space, and 
hypokalemia results from metabolic alkalosis due to the 
cellular uptake of potassium.16
- When calculating the potassium intake, the amount 
infused as drug salts should be taken into account.2 
- If potassium requirements are much higher than 
recommended, the baseline intake should be provided 
by PN and the supplemental amount infused by an 
independent line through a Y-connection system with 
PN infusion, using for example KCl 7.5% (1 mL = 1 mEq); 
this method is convenient for adjusting the intake 
according to the serum potassium levels.
Parameters guiding the prescription:
- Serum potassium levels: Reference values 3.5-4.5 
D - day; LoE - level of evidence.
* Higher intakes may be necessary: 3 mEq/kg/day.
† Higher intakes may be necessary: 7 mEq/kg/day.
Table 1. Daily intakes of sodium (mEq/kg) recommended by parenteral nutrition (LoE 4)2
Postnatal days D1-3 D4-5 ≥ D6
Term infants 0-2 1-3 2-3
Preterm infants > 1500 g 0-2* 2-5 3-5
Preterm infants < 1500 g 0-2*,† 2-5† 3-5†
D - day; LoE - level of evidence.
Table 2. Daily intakes of chloride (mEq/kg) recommended by parenteral nutrition (LoE 4)2
Postnatal days D1-3 D4-5 ≥ D6
Term and preterm infants 0-3 2-5 2-5
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mEq/L.3 
- Urine output.6
1.4. Calcium and phosphorus (Table 4)
Comments:
- Calcium (Ca): 1 mmol = 2 mEq = 40 mg.3 
- Phosphorus (P): 1 mmol = 31 mg; the valency of 
phosphorus varies  whether it is in the form of monobasic 
or dibasic phosphate.3,18 
- In relation to the previous ESPGHAN recommendation,19 
much higher doses of calcium and phosphorus are 
currently proposed for growing preterm infants,17 which 
raises concerns about its compatibility and stability in 
PN solutions and the risks of precipitation.20
- The use of organic salts of calcium and phosphorus 
and a pH < 7.1 in the final solution, which promotes the 
formation of dibasic calcium phosphate (60 times more 
compatible than monobasic), are the main determinants 
for good calcium and phosphorus compatibility in 
neonatal PN solutions.17,18,20
- Several studies have evaluated the compatibility of 
calcium and phosphorus in neonatal PN solutions,20-23 
although a good compatibility is not a guarantee of 
good bone deposition.18 To date, only three trials have 
assessed the effect of different parenteral doses of 
calcium and phosphorus24,25 and different Ca:P ratios26 
on bone mineralization relying on image methods. This 
insufficient information may explain why the parenteral 
doses suggested for preterm infants are relatively wide 
(Table 4). 
- Using the previously recommended Ca:P ratio of mg:mg 
1.7:1 (1.3:1 molar) for preterm infants,19 hypercalcemia, 
hypophosphatemia, and hypokalemia frequently 
occurred in the presence of the recommended doses 
of amino acids (> 2.5 g/kg/day).27,28 This was due to 
the cellular growth induced by a good supply of amino 
acids, leading to intracellular mobilization of potassium 
and phosphorus and consequent hypokalemia, 
hypophosphatemia, and bone calcium mobilization in 
response to hypophosphatemia.27 A recent study in very 
preterm infants29 showed that during the first postnatal 
week the use of a ratio Ca:P mg:mg of 1.3:1 (or 
equimolar 1:1) based on increased dose of phosphorus, 
solved the problem (LoE 2, RG B). In this study,29 
calcium, and phosphorus concentrations of 1.7 mmol/L 
in the final PN solution, corresponding to 68 mg/dL of 
calcium, and 52.7 mg/dL of phosphorus, were used.   
- The lack or scarcity of studies testing both the mineral 
compatibility and stability in neonatal PN solutions 
and the impact on serum electrolytes balance of high 
calcium and phosphorus doses currently recommended 
by ESPGHAN/ESPEN/ESPR/CSPEN17 (Table 4) is effectively 
a matter of concern. To ensure such safety, these 
studies need to control the principal factors interfering 
with mineral compatibility and stability, such as the 
organic or inorganic nature of the different calcium and 
phosphate salts available, Ca:P ratios, pH values in the 
final solution, amino acid concentrations, temperatures, 
and storage durations.18 
- There is no robust evidence assuring the mineral 
compatibility and stability of the high mineral doses 
currently recommended,17 using different available 
types and concentrations of amino acid solutions 
and phosphate salts, and different final pH of PN 
solutions.30,31 Therefore, the suggested alternative is to 
use at least the following values29: calcium 88-90 mg/
kg/day, phosphorus 68-70 mg/kg/day, with a molar 
Ca:P ratio of 1 (or 1.3:1 in mg). During the first postnatal 
days, the doses should not exceed the concentrations of 
calcium 68 mg/dL and phosphorus 52.7 mg/dL.29
- When choosing to administer phosphorus in the first 
postnatal day, it is necessary to consider the appreciable 
amount of sodium contained in most phosphorus 
salts (e.g. 2 mEq of sodium per 1 mL of sodium 
LoE - level of evidence.
Table 3. Daily intakes of potassium recommended by parenteral 
nutrition (LoE 4)3,7,9
- Onset: After the first postnatal day provided urine output is ≥ 1 
mL/kg/h
- Requirements according to maturity and body weight:
Term infants: 1-3 mEq/kg
Preterm infants > 1,500 g: 1-3 mEq/kg 
Preterm infants < 1,500 g: 1-2 mEq/kg
Ca - calcium; LoE - level of evidence; P - phosphorus; RG - recommendation grade.
Table 4. Daily intakes of calcium and phosphorus recommended by parenteral nutrition (LoE 2,3,4, RG 0)17
Term infants Preterm infantsFirst postnatal week
Preterm infants
After first postnatal week
Calcium                                 mg/kg 30-60 32-80 100-140
mmol/kg 0.8-1.5 0.8-2.0 2.5-3.5
Phosphorus                           mg/kg 20.40 31-62 77-108
mmol/kg 0.7-1.3 1.0-2.0 2.5- 3.5
Ca:P ratio                             mg:mg 1.3-1.7 1.3 1.3-1.7
molar 1.0-1.3 1.0 1.0-1.3
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glycerophosphate).
- Solutions with high calcium concentrations should be 
administered by central venous catheter, due to the risk 
of tissue necrosis when extravasation occurs using the 
peripheral infusion.32
- Calcium gluconate should be packaged in polyethylene 
vials and not in glass vials because they are associated 
with aluminum contamination (LoE 3, RG B).17
Parameters guiding prescription:
- Serum phosphorus and alkaline phosphatase levels: A 
systematic review concluded that there are no reliable 
early biochemical markers for metabolic bone disease of 
prematurity.33 Nevertheless, among the most commonly 
used, hypophosphatemia (< 5.5 mg/dL or < 1.8 mmol/L) 
and elevation of alkaline phosphatase (> 900 IU/L), 
particularly the combination of both, are the markers 
with higher sensitivity and specificity, whereas serum 
calcium level is a poor marker.33,34
- In very and extremely preterm infants, hypokalemia, 
hypophosphatemia, and hypercalcemia should be 
monitored when Ca:P ratios higher than 1.3:1 (or molar 
1:1) are used.27
1.5. Magnesium (Table 5)
Comments:
- Magnesium (Mg): 1 mmol = 2 mEq = 24 mg.3
- Particularly in preterm infants in the first postnatal 
days, parenteral magnesium should only be initiated 
when serum magnesium levels are within normal 
limits,3 due to limited renal capacity to excrete it and 
the possible prenatal exposure to magnesium sulfate 
used as tocolytic (LoE 2, RG B).17
Parameter guiding the prescription:
- Serum magnesium levels: reference values for term 
and preterm infants 0.7-1.5 mEq/L.17
1.6. Water-soluble vitamins (Table 6)
Comments:
- Although the optimal parenteral doses of most vitamins 
have not yet been determined in newborn infants, Table 
6 indicates the recommended doses for water soluble 
vitamins35
- Vitamins should be administered daily (LoE 4, RG 0).35
- Following the manufacturer’s instructions, the content 
of one vial of Soluvit® N (Fresenius Kabi) should be 
dissolved in 10 mL of water for injections or glucose 
solution for infusion (5%-50%). 
- Water-soluble vitamins should be added to the lipid 
emulsion or to lipid-containing mixtures in order to 
increase their stability (LoE 4, RG 0).35
- Suggestion: Soluvit N® (Fresenius Kabi), daily dose of 
1 mL/kg, 1 mL containing vitamin C 10.0 mg, thiamine 
0.25 mg, riboflavin 0.36 mg, niacin 4.0 mg, pyridoxine 
0.40 mg, vitamin B12 0.5 μg, pantothenic acid 1.50 mg, 
biotin 6.0 μg, and folic acid 40 μg. First, the lyophilisate 
powder of a Soluvit N® (Fresenius Kabi) vial content 
is reconstituted with 10 mL of water for injection or 
5%-50% glucose solution for infusion; secondly, the 
prescribed volume of Soluvit N® (Fresenius Kabi) is 
withdrawn from the vial and mixed with the prescribed 
volume of Vitalipid N Infant® (Fresenius Kabi); finally, the 
mixture of both water- and fat-soluble vitamins is added 
directly to the lipid emulsion.  
1.7. Lipid soluble vitamins (Table 7)
Comments:
- Vitamin A 1 μg = 3.33 UI; vitamin D 1 μg = 40 UI; 
vitamin E 1 mg = 1 UI.36  
- Vitamins should be administered daily (LoE 4, RG 0).35
- The dose of vitamin K1 provided by fat soluble vitamin 
solutions for PN assumes that vitamin K1 has been 
administered on the first postnatal day to prevent the 
hemorrhagic disease of the newborn.35 
- Fat soluble vitamins should be added to the lipid 
emulsion or to lipid-containing mixtures in order to 
increase their stability (LoE 4, RG 0).35
- Suggestion: Vitalipid N Infant® (Fresenius Kabi): If body 
weight < 2.5 kg, the daily dose is 4 mL/kg; if > 2.5 kg, 
the maximum daily dose is 10 mL. Each 1 mL of Vitalipid 
N Infant® (Fresenius Kabi) contains vitamin A 69 μg (230 
IU), vitamin D2 1 μg (40 IU), vitamin E 0.64 mg (0.70 IU), 
and vitamin K1 20 μg.
1.8. Trace elements (Table 8)
Comments: 
- The major transfer of trace elements to the fetus occurs 
in the third trimester. Although optimal parenteral doses 
of most trace elements have not yet been determined 
Guidelines for Neonatal Parenteral Nutrition
Table 5. Daily intakes of magnesium recommended in parenteral nutrition (LoE 2,3,4, RG 0)17
Term infants Preterm infantsFirst postnatal week
Preterm infants
After first postnatal week
Magnesium                           mg/kg 2.4-5.0 2.0-5.0 5.0-7.5
mmol/kg 0.1-0.2 0.1-0.2 0.2-0.3
mEq/kg 0.2-0.4 0.2-0.4 0.4-0.6
LoE - level of evidence; RG - recommendation grade.
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in preterm infants, Table 8 indicates the recommended 
doses.36,37
- It is suggested that zinc should be administered from 
the beginning of exclusive PN.19
- The commonly used trace elements solutions include 
manganese and molybdenum, which are only recommended 
in prolonged PN (> 2 weeks).37
- There are no recommendations on parenteral fluoride 
supplementation in newborns.38
- Parenteral nutrition solutions are generally contaminated 
with aluminum and chromium in doses that meet the 
requirements and, therefore, parenteral supplementation 
is not necessary.37
- Iron contributes to oxidative stress, and parenteral iron 
should not be given routinely if duration of PN is less than 
three weeks (LoE 4, RG 0). Iron supplementation should 
preferentially be given enterally; if this is not possible and 
exclusive PN is prolonged for more than three weeks, 
consider parenteral iron supplements (LoE 4, RG 0).37
- In cholestasis and hepatic insufficiency, doses of copper 
and manganese should be reduced to avoid toxicity (LoE 
3, RG 0).37 In acute renal failure, the dose of selenium 
should be reduced (NE 4, GR 0).37 The same would be 
indicated for chromium, but this is not included in the 
composition of most trace element solutions for newborn 
infants.39 If the volume of the trace elements solution 
is reduced or suspended, the dose of zinc should be 
adjusted.39
- Suggestion: PN solution should be supplemented 
with zinc gluconate 0.1% (1 mL = 1000 μg zinc) from 
its beginning. After two weeks of exclusive PN, a 
complete solution of trace elements should be given; 
e.g. Peditrace® (Fresenius Kabi) at daily dose of 1 mL/kg, 
1 mL containing: zinc 250 μg, copper 20 μg, manganese 
1 μg, selenium 2 μg, iodine 1 μg and fluoride 57 μg. 
While in term infants this solution provides sufficient 
zinc, in preterm infants it is necessary to add zinc 
gluconate 0.1% to make up the recommended dose of 
zinc (Table 8).37 If iron supplementation is needed by PN, 
the daily dose is 50-100 μg/kg in term infants and 200-
259 μg/kg in preterm infants (LoE 4, RG 0).37 
2. Commercial ready-to-use parenteral 
nutrition solutions
As an alternative to individualized PN prescription with 
hospital pharmacy compounding, commercial ready-
LoE - level of evidence; RG - recommendation grade.
* LoE 3, GR 0.
Table 6. Daily intakes of water soluble vitamins recommended by 
parenteral nutrition in term and preterm infants35
Vitamin Dose/kg
Vitamin C (ascorbic acid) (mg)* 15-25
Thiamine (vitamin B1) (mg) 0.35-0.5
Riboflavin (vitamin B2) (mg) 0.15-0.2
Pyridoxine (vitamin B6) (mg) 0.15-0.2
Niacin (nicotinamide or vitamin B3) (mg) 4.0-6.8
Vitamin B12 (cobalamin) (mg) 0.3
Pantothenic acid (vitamin B5) (mg) 2.5
Biotin (vitamin B7) (µg) 5.0-8.0
Folic acid (µg)* 56
LoE - level of evidence; RG - recommendation grade.
* LoE 3, RG 0. 
† LoE 2+, RG B.
‡ Maximum 11 mg/day.
§ Current multivitamin solutions provide higher doses.
Table 7. Daily intakes of lipid soluble vitamins recommended for parenteral nutrition in term and preterm infants35
Vitamin Term infants Preterm infants
Vitamin A (retinol)*                                                 IU
μg
 150-300/kg or 697/day
2,300/day
 227-455/day or 700-1,500/kg
227-455/kg
Vitamin D (calciferol)*                                             IU  40-150/kg or 400/day 80-400/kg or 200-1,000/day






Vitamin K (phytomenadione)*                               μg 10/kg§ 10/kg§ 
Table 8. Daily intakes of trace elements recommended by 
parenteral nutrition (LoE 4, RG 0)37
Trace element Term infants Preterm infants
Zinc (μg/kg) 250 400-500
Copper (μg/kg) 20 40
Selenium (μg/kg) 2.3 7
Chromium (μg/kg) 0 0
Manganese (μg/kg) 1 1
Molybdenum (μg/kg) 0.25 1
Iodine (μg/kg) 1-10 1
Iron (μg/kg) 50-100 200-250
LoE - level of evidence; RG - recommendation grade.
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to-use neonatal PN solutions with fixed composition 
are currently available.40 Potential advantages of 
these ready-to-use solutions include improved 
physical-chemical stability of solutions and macro and 
micronutrient intakes, cost-effectiveness, reduction of 
prescription errors and bacterial contamination, and 
24-hour availability in any day of the week without 
dependence on pharmaceutical services.9,36 For these 
reasons, these ready-to-use neonatal PN solutions are 
recommended over individualized PN prescription with 
hospital pharmacy compounding, including for preterm 
infants, provided that they are stable and the ready-to-
use solutions are used for less than 2-3 weeks, under 
adequate laboratory monitoring.40 The ready-to-use 
PN solutions should not be used in very and extremely 
preterm infants at risk of metabolic imbalances, such as 
hypo- and hyperglycemia, hypo- and hypernatremia, and 
hypo- and hyperkalemia, conditions that may require 
frequent adjustments of macro and micronutrients (LoE 
2, RG B).40   
In Portugal, the ready-to-use Numeta® (Baxter) neonatal 
PN solutions are currently commercialized, and the 
Instituto Nacional da Farmácia e do Medicamento 
(INFARMED) has recently issued the marketing 
authorization for ready-to-use Pediaven NN® (Fresenius 
Kabi) neonatal PN solutions (Appendix 3).
Numeta® (Baxter) solutions
A study has compared effects, on nutrient intakes 
and costs, of the ready-to-use Numeta® (Baxter) PN 
solutions versus individualized PN prescription with 
hospital pharmacy compounding, in preterm infants.41 
It was concluded that Numeta® (Baxter) is an alternative 
to individualized PN for infants > 1,000 g in the period of 
stable growth; it is more expensive than individualized 
PN but it saves human resources.41.    
According to the manufacturer specifications, Numeta 
G13% E® (Baxter) (Appendix 3, Supplementary Table 1) 
is indicated for preterm infants and Numeta G16% E® 
(Baxter) (Appendix 3, Supplementary Table 2) for term 
infants. They are composed of three-compartment 
bags, containing a solution of glucose, one of amino 
acids (Primene®, Baxter) with electrolytes, and a lipid 
emulsion, respectively. At the time of administration, 
the removal of the seal between the glucose and amino 
acid/electrolyte compartments is activated and, when 
lipids are to be administered, the seal is removed from 
the respective compartment.
Numeta® (Baxter) solutions do not contain vitamins or 
trace elements, which must be added when they are 
administered.
Comments:
- Numeta G13% E® (Baxter): Is designed to provide 
aggressive nutrition in low volume (about 140 mL/
kg/day) to very preterm infants. When such volume 
is exceeded, the recommended intake of nutrients 
is exceeded. If 140 mL/kg/day is administered even 
when activating the lipid compartment, the maximum 
recommended intake of amino acids is exceeded, and 
the maximum recommended dose of glucose (Part I, 
sections 11.3 and 11.4) is reached or exceeded; e.g. in 
an infant weighing 1,000 g, the amino acids and glucose 
intakes will be 4.34 g/kg/day (Part I, section 11.4) and 
12.9 mg/kg/min (Part I, section 11.3), respectively. 
- For both Numeta G13% E® and G16% E® (Baxter) 
solutions, the manufacturer accepts the addition 
of water for injections or other solutions to reduce 
potential exaggerated concentration of certain nutrients 
(e.g. glucose); however, this procedure has the inherent 
disadvantage of diluting and decreasing the desirable 
intake of other nutrients, in addition to the drawbacks 
related to the manipulation itself.
- Numeta G13% E® and G16% E® (Baxter) solutions 
contain an appreciable amount of sodium, chloride, and 
potassium; therefore, it is advisable to use these solutions 
carefully on the first postnatal day or days, especially in 
preterm infants (Part II, sections 1.1, 1.2, and 1.3).
Pediaven® (Fresenius Kabi) solutions
- Pediaven NN1® (Fresenius Kabi) (Appendix 3, 
Supplementary Table 3) and Pediaven NN2® (Fresenius 
Kabi) (Appendix 3, Supplementary Table 4) have been 
designed for newborn infants. Both solutions contain no 
lipids, and the chosen lipid emulsion should be infused 
via a Y-connection system (Part I, section 6). These 
solutions contain trace elements but not vitamins, 
which must be added when they are administered. The 
amino acids have the profile of Vaminolact® (Fresenius 
Kabi). Both solutions have osmolarities which allow 
their peripheral infusion. 
- According to the manufacturer, Pediaven NN1® 
(Fresenius Kabi) is indicated for term and preterm 
infants in the first 24 to 48 postnatal hours. It contains 
neither potassium nor phosphorus and has a residual 
amount of sodium. Pediaven NN2® (Fresenius Kabi) is 
indicated for term and preterm infants more than 2 
postnatal days old.
Comments:
- Pediaven NN1® and Pediaven NN2® (Fresenius Kabi) 
solutions have been introduced very recently and a 
clinical study has shown that they are safe.38 In addition, 
the solutions have osmolarities < 800 mOsm/L, so they 
can be infused peripherally.42
- Since Pediaven NN1® and Pediaven NN2® (Fresenius 
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Kabi) solutions were designed both for term and preterm 
infants, they provide lower than recommended doses 
of certain nutrients for very and extremely preterm 
infants1; e.g. in an infant weighing 1,000 g who is 
receiving 150 mL/kg/day of Pediaven NN2®, this provides 
2.55 g/kg/day of amino acids (Part I, section 11.4) and 
45.75 mg/kg/day of calcium (Part II, section 1.4). 
3. Particular conditions
3.1. Sepsis
In the acute phase of sepsis, hyperglycemia 
may occur due to increased insulin resistance and 
hypertriglyceridemia due to elevated catecholamines 
and cortisol and decreased lipoprotein lipase activity.43 
When sepsis is complicated with thrombocytopenia, 
there is no evidence that intravenous lipids decrease 
the number or the function of platelets, which may 
be due to vitamin E deficiency and heparin infusion, 
respectively. In the acute phase of sepsis, increased 
need of amino acids has not been demonstrated, and 
the excess of nutrients during the catabolic phase can 
be counterproductive.44 In necrotizing enterocolitis, in 
particular, energy and protein metabolism rates are 
similar to those of stable infants.45
Approach: 
1) Glucose should be the preferred energy source; if 
hyperglycemia (> 145 mg/dL) occurs, glucose intake 
should be reduced, if necessary, to 2.5 mg/kg/min in 
term infants and 4 mg/kg/min in preterm infants46,47; 
2) If hypertriglyceridemia (> 265 mg/dL) occurs, the 
lipid intake should be reduced, if necessary, to 1 g/kg/
day to avoid essential fatty acid deficit, with an apparent 
advantage of emulsions containing fish oil48; 
3) In the acute phase of sepsis, a daily intake of at least 60 
kcal/kg and 2.5 g/kg of amino acids should be guaranteed.49
3.2. Cholestasis
In newborn infants, PN associated cholestasis is 
multifactorial. A multivariate analysis has identified 
as independent factors the duration of PN and a high 
dose of glucose, but not the doses of lipids or amino 
acids.50 A systematic review in newborns and children 
corroborated that PN duration is a preponderant risk 
factor.51 Concerning components of lipid emulsions, it 
seems that a high content of phytosterols and n-6 fatty 
acids and a low a-tocopherol content predispose to 
PN associated cholestasis, while high fish oil contents 
protects against it.50,52 
The potential toxicity of copper and manganese in 
cholestasis, due to the difficulty of their excretion by 
bile, should be taken into account.19,39
Approach: 
To prevent or mitigate PN associated cholestasis 
(conjugated bilirubin > 2 mg/dL), it is recommended that: 
1) The dose of glucose be reduced, perhaps to levels that 
do not exceed its oxidative capacity (Part I, section 11.3); 
2) Enteral nutrition be increased and PN reduced or 
suspended as possible; 
3) Lipid emulsions containing fish oil and α-tocopherol 
should be preferred (Part I, section 11.5); 
4) Depending on the severity of cholestasis, the dose 
of trace elements solution containing copper and 
manganese should be suspended or reduced (Part II, 
section 1.8).
3.3. Serum unconjugated bilirubin
In preterm infants, controversy exists about the 
possibility that free fatty acids resulting from the 
hydrolysis of serum triglycerides displace bilirubin from 
binding sites on albumin, thus potentially elevating the 
free fraction of bilirubin to neurotoxic levels. 53,54 This 
does not appear to occur if the molar ratio free fatty 
acid: albumin is < 6.54 In other words, it is less likely to 
occur if serum albumin levels are within the reference 
range. Given this uncertainty, some authors propose 
to reduce the dose of lipids when serum unconjugated 
bilirubin exceeds 10 mg/dL.34,55 
Approach: 
In preterm infants, it is prudent to reduce the dose of lipids 
if serum unconjugated bilirubin levels exceed 10 mg/dL.
3.4. Pulmonary hypertension
In term and preterm infants, intravenous lipid infusion 
may aggravate pulmonary hypertension, with dose- and 
time-dependent effects.54
Approach: 
In severe pulmonary hypertension it is prudent to 
temporarily suspend the lipids or decrease their dose 
to 1 g/kg/day.48
3.5. Major surgery
Newborn infants undergoing major surgery who were 
adequately anesthetized and receiving appropriate 
analgesics will at most need a slight increase in energy 
intake (about 15%) in the immediate postoperative 
period (about 4 h after surgery).56 During this period, it 
has also been shown that the protein turnover does not 
increase significantly.45
In case of extensive bowel resection, ranitidine is 
effective in reducing gastric hypersecretion that may 
cause hydroelectrolytic imbalance.2
Approach: 
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In the first postoperative days there is no need to increase 
the energy and protein intakes if analgesia is adequate. 
In case of extensive bowel resection, ranitidine may be 
prescribed at a dose of 10-15 mg/kg/d.
4. Conclusions
Research has contributed to the better compatibility of 
higher mineral concentrations and adequate calcium to 
phosphorus ratios in PN solutions in order to optimize 
mineral deposition in the skeleton.
There are particular conditions, such as the acute phase 
of sepsis, pulmonary hypertension, and PN associated 
cholestasis, under which the dose of nutrients need to 
be adjusted.
As an alternative to the individualized PN prescription 
with hospital pharmacy compounding, commercial 
ready-to-use PN solutions with a guaranteed stability 
of nutrients are available, reducing preparation errors 
and microbial contamination. Due to their advantages, 
they have been recommended over individualized PN. 
However, they often require the addition of solutions or 
the simultaneous infusion of solutions to correct ionic 
and metabolic imbalances, with inherent inconvenience. 
This update of the guidelines for neonatal PN prescription 
represents a general orientation to support the clinical 
practice that should be adapted to each case.
APPENDIX 3 - Numeta® (Baxter) and Pediaven® (Fresenius Kabi) 
ready-to-use neonatal parenteral nutrition compositions
Supplementary Table 1. Numeta G13%E® (Baxter) composition
Per 100 mL Without lipids With lipids
Total energy (kcal) 82 91
Amino acids (g) 3.9 3.1
Glucose (g) 16.7 13.3
Lipids (g) 0 2.5
Sodium (mEq) 2.7 2.2
Chloride (mEq) 3.9 3.1
Potassium (mEq) 2.6 2.1
Magnesium (mmol)

















Osmolarity (mOsm/L) 1,400 1,150
Supplementary Table 2. Numeta G16%E® (Baxter) composition
Per 100 mL Without lipids With lipids
Total energy (kcal) 96 103
Amino acids (g) 3.4 2.6
Glucose (g) 20.6 15.5
Lipids (g) 0 3.1
Sodium (mEq) 3.1 2.4
Chloride (mEq) 3.7 2.8
Potassium (mEq) 3 2.3
Magnesium (mmol)

















Osmolarity (mOsm/L) 1,585 1,230
Supplementary Table 3. Pediaven® NN1 (Fresenius Kabi) composition 
per 100 mL
Total energy (kcal) 46

















                     (mg)
715
Osmolarity (mOsm/L)
Supplementary Table 4. Pediaven® NN2 (Fresenius Kabi) 
composition per 100 mL
Total energy (kcal) 47

















                     (mg)
790
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